| index | Title |
| 1 | Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches Author(s):Tianning GU, Meng ZHU, He HUANG, Y... Clicked:3589 Download:3328 Cited:0 <Full Text> <PPT> 1495 Journal of Zhejiang University Science B 2022 Vol.23 No.10 P.793-811 DOI:10.1631/jzus.B2200256 |
| 2 | Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with ext... Author(s):Delin KONG, Tingting YANG, Jia GEN... Clicked:3757 Download:3120 Cited:0 <Full Text> <PPT> 1560 Journal of Zhejiang University Science B 2022 Vol.23 No.10 P.876-880 DOI:10.1631/jzus.B2200128 |
| 3 | Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy Author(s):Yang YANG, Xiaolin GU, Jingsong HE... Clicked:2710 Download:3697 Cited:0 <Full Text> <PPT> 1078 Journal of Zhejiang University Science B 2024 Vol.25 No.8 P.719-722 DOI:10.1631/jzus.B2300835 |
| 4 | Relapse mechanisms and disease management strategies after BCMA CAR-T therapy for multiple myeloma Author(s):Jiahao HE1,2,Clicked:269 Download:269 Cited:0 <Full Text> Journal of Zhejiang University Science B 1998 Vol.-1 No.-1 P. DOI:10.1631/jzus.B2500466 |